Eli Lilly and Company $LLY Shares Bought by WASHINGTON TRUST Co

WASHINGTON TRUST Co grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,294 shares of the company’s stock after acquiring an additional 491 shares during the quarter. WASHINGTON TRUST Co’s holdings in Eli Lilly and Company were worth $20,735,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Viawealth LLC boosted its position in shares of Eli Lilly and Company by 7.2% during the fourth quarter. Viawealth LLC now owns 535 shares of the company’s stock worth $575,000 after buying an additional 36 shares during the period. Triodos Investment Management BV acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $24,273,000. Keyvantage Wealth LLC boosted its position in shares of Eli Lilly and Company by 80.1% during the fourth quarter. Keyvantage Wealth LLC now owns 616 shares of the company’s stock worth $662,000 after buying an additional 274 shares during the period. Impact Partnership Wealth LLC boosted its position in shares of Eli Lilly and Company by 520.5% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,843 shares of the company’s stock worth $1,981,000 after buying an additional 1,546 shares during the period. Finally, Norges Bank acquired a new stake in Eli Lilly and Company in the fourth quarter worth about $12,976,634,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, meaning all three major PBMs now cover Lilly’s full obesity portfolio. That should expand access for millions of patients and strengthen Lilly’s market share versus Novo Nordisk. Article Title
• Positive Sentiment: Reuters also reported that Mounjaro outperformed other GLP-1 drugs in some type 2 diabetes patients, reinforcing Lilly’s competitive edge in the diabetes and obesity markets. Article Title
• Positive Sentiment: Wall Street is also reacting to Lilly’s broader pipeline momentum, including positive Phase 1b data for Verve-102 and progress in olomorasib, which supports the view that Lilly is more than just a weight-loss story. Article Title
• Positive Sentiment: Lilly announced a major push into vaccines, including the planned acquisition of Curevo Vaccine for $1.5 billion and other vaccine-developer deals, signaling a new long-term growth avenue outside cardiometabolic care. Article Title
• Positive Sentiment: Analyst and media coverage has been upbeat, with commentary highlighting Lilly’s “brilliant management,” record valuation, and strong pipeline, which can help sustain momentum in the stock. Article Title

Eli Lilly and Company Price Performance

LLY stock opened at $1,105.37 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,149.10. The firm has a market capitalization of $1.04 trillion, a PE ratio of 39.27, a P/E/G ratio of 1.23 and a beta of 0.48. The firm has a 50-day moving average of $955.92 and a two-hundred day moving average of $1,009.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period in the prior year, the firm earned $3.34 earnings per share. The business’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analysts Set New Price Targets

Several research firms recently weighed in on LLY. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Scotiabank restated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Berenberg Bank upped their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. Finally, JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.